KT-621 achieved deep STAT6 degradation across both the 100 mg and 200 mg dose groups tested, with median reductions of 94% and 98% in skin and blood, respectively, demonstrating strong translation ...

Silent Sinus Syndrome causes subtle facial changes from chronic sinus blockage Expert explains how to spot it early and ...

Company to host video conference call and webcast at 8:00 a.m. ET on Monday, December 8, 2025 ...

Chronic rhinosinusitis is a chronic inflammatory condition of the paranasal sinuses and nasal cavities, affecting an ...

Celltrion receives US FDA approval of 300mg strength of Omlyclo, the first and only interchangeable biosimilar to Xolair: Incheon, South Korea Thursday, December 4, 2025, 11:00 Hr ...

Denmark: A new systematic review and meta-analysis has shed light on how effectively biologic therapies can help restore the ...

Celltrion, Inc. today announced the U.S. Food and Drug Administration (FDA) has approved a new presentation of OMLYCLO® (omalizumab-igec), the first and only biosimilar designated as interchangeable ...

Summary • Lyra Therapeutics, Inc. stock rose 13.9% to $4.25 following a corporate update on third-quarter results.• The update included plans for a Phase 3 clinical trial for LYR-210, aimed at chronic ...

Detailed price information for Upstream Bio Inc (UPB-Q) from The Globe and Mail including charting and trades.

Winter allergies or chronic sinusitis? On National Pollution Control Day, experts decode how pollution worsens sinus issues ...

A study published this week by the journal Laryngoscope Investigative Otolaryngology reports that adults who use marijuana ...